Liver Fibrosis Clinical Trial
Official title:
A Multicentre Clinical Trial in HBsAg Seroclearance After Receiving Combined Therapy of Peginterferon and Tenofovir in Nucleos(t)Ide Analogue-treated Patients With HBV Related Liver Fibrosis.
Liver fibrosis caused by hepatitis B virus (HBV) infection is easy to progress to liver cirrhosis and liver cancer, with great harm and poor therapeutic effect. Nucleos(t)ide analogues (NAs) are the most commonly anti-HBV drugs currently . Long-term use of NAs can inhibit HBV DNA and achieve the purpose of reducing poor prognosis. However, adverse prognosis, such as liver cirrhosis and liver cancer, cannot be completely eliminated even under the status of virologic inhibition under THE action of NAs. Current studies have shown that the lower the HBV surface antigen (HBsAg) is, the better the long-term prognosis is. As another anti-HBV drug, pegylated-interferon-α (peg-IFN-α) has the immune regulation effect that NAs do not have, which can bring irreplaceable effects in HBsAg reduction and liver fibrosis reversal. Therefore, the combined therapy of NAs and peg-IFN-α is a hot issue in the field of liver diseases over the world, but the research and application of the combined therapy in patients with liver fibrosis are very few. The preliminary results of our previous research showed that the combined therapy of peg-IFN-α and NAs in patients with HBV related fibrosis were safe, and had a significant effect on HBsAg decline. On this basis, this study intends to carry out a multicentre, non-randomized concurrent controlled trial, comparing the safety and efficacy between combined therapy (peg-IFN-α plus tenofovir) and tenofovir monotherapy in patients with liver fibrosis, especially focusing on HBsAg's decline and clearance, and the improvement of liver fibrosis degree, in order to find a better therapy, and to guide the clinical decision making.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
| Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
| Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
| Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
| Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
| Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
| Not yet recruiting |
NCT01133184 -
Improved Prevention of Perinatal Hepatitis B Transmission
|
Phase 4 | |
| Completed |
NCT00043303 -
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
|
Phase 2 | |
| Completed |
NCT03872024 -
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
|
N/A | |
| Recruiting |
NCT05912179 -
Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
|
||
| Recruiting |
NCT04533828 -
68Ga-FAPI PET/CT in Liver Fibrosis Patients
|
Early Phase 1 | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
| Completed |
NCT01707472 -
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
|
Phase 2 | |
| Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
| Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
| Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
| Completed |
NCT00049842 -
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT06063785 -
Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis
|